MTTI Reports Fast-Acting Sprayable Molecule for Real-Time Fluorescence-Guided Tumor Surgery

Molecular Targeting Technologies, Inc. (MTTI) will present updates about its exclusive near-infrared fluorescent dye, CypH-11 (Cmetglo), at the World Molecular Imaging Conference (WMIC) in Montreal from September 9-13, 2024, and at the Peritoneal Surface Oncology Group International (PSOGI) meeting in Lyon from September 26-28, 2024. This innovative and rapid-acting technology shows potential as a significant real-time aid for oncologists in fluorescence-guided surgery (FGS). By enabling surgeons to visualize tiny tumor residues, Cmetglo can facilitate a more complete resection of cancer within the abdominal cavity, potentially enhancing patient outcomes by minimizing harm to surrounding healthy tissues and extending progression-free survival for those with peritoneal surface malignancies (PM).

Dr. Johnny Ong, an Associate Professor at the Department of Sarcoma, Peritoneal and Rare Tumors at the National Cancer Centre Singapore, noted the challenges in differentiating between tumors and normal or scar tissues during cytoreductive surgery (CRS). The research team conducted ex vivo validation of patient tissues to assess Cmetglo's clinical utility for detecting PM using a topical application. Preliminary findings indicate that Cmetglo may prove most beneficial for patients with colorectal cancer, with the potential for broader application across various histological subtypes.

Dr. Brian D Gray, who leads Research and Development at MTTI, emphasized that Cmetglo enhances visibility by making tumor margins and metastases glow under near-infrared light. This feature could be a crucial addition to the tools available to surgeons seeking to maximize cytoreduction during FGS.

Additionally, Dr. Seung Koo Lee, an Assistant Professor at Weill Cornell Medicine, stated that CypH-11 is a sprayable, pH-responsive fluorogenic probe that remains minimally fluorescent at neutral pH levels but emits a bright fluorescence in acidic environments, which are typical of cancer cell proliferation. The capability of CypH-11 to detect small ovarian tumors was further evidenced through its application in a high-grade serous ovarian cancer (HGSOC) model.

Chris Pak, President and CEO of MTTI, expressed that this revolutionary molecule exemplifies MTTI's tradition of innovation in targeted diagnostics and therapeutics. The company is exploring the use of Cmetglo in colorectal, ovarian, and brain cancers, thereby providing value to patients, surgeons, and other stakeholders.

Molecular Targeting Technologies, Inc. (MTTI) is a private, clinical-stage biotechnology company focused on developing targeted radiotherapeutics for rare cancers. The company is dedicated to translating pioneering diagnostics and radiopharmaceuticals into clinical applications to enhance human health.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!